Top Stocks
Stock Comparison
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Taysha Gene Therapies Stock Analysis & Ratings
TSHA Stock Chart & Stats
Day’s Range$2.81 - $3.14
52-Week Range$2.69 - $26.99
Previous Close$2.98
Volume119.83K
Average Volume (3M)262.12K
Market Cap$115.56M
P/E Ratio-0.6
Beta2.24
Next EarningsAug 15, 2022
EPS Forecast-$1
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$28.33
Smart Score8
EPS (TTM)-5.07
Taysha Gene Therapies News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $2.69 and its highest was $26.99 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Taysha Gene Therapies’s market cap is $115.56M.
What is Taysha Gene Therapies’s price target?
The average price target for Taysha Gene Therapies is $28.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $20.00. The average price target represents 894.04% Increase from the current price of $2.85.
The highest analyst price target is $37.00 ,the lowest forecast is $20.00. The average price target represents 894.04% Increase from the current price of $2.85.
What do analysts say about Taysha Gene Therapies?
Taysha Gene Therapies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Aug 15, 2022 which is in 87 days.
How were Taysha Gene Therapies’s earnings last quarter?
Currently, no data Available
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 40,550,000 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Among the largest hedge funds holding Taysha Gene Therapies’s share is Perceptive Advisors LLC. It holds Taysha Gene Therapies’s shares valued at N/A.
---
Taysha Gene Therapies Stock Analysis
Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Price Target
$28.33
Strong Buy▲(894.04% Upside)
Analyst Forecast
Strong Buy
Average Price Target: $28.33
Blogger Sentiment
Bullish
TSHA Sentiment 100% Sector Average 70%
Hedge Fund Holdings
▼ Decreased
By 320.4K Shares Last Quarter.
Insider Transactions
N/A
Currently Not Enough Data Available
Retail Investors
Very Negative
Last 7 Days ▲ 0.2% Last 30 Days ▼ 3.7%
News Sentiment
Positive
Bullish 100% Bearish 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.31%
12-Months-Change
Fundamentals
Return on Equity
-140.80%
Trailing 12-Months
Asset Growth
-31.65%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
---
---